drugset / Trial / NCT06922903
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NaSingle-groupOpen-labelDiagnostic
Summary
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in patients with Prostate Cancer
Timeline
- Start
- 2025-04
- Primary completion
- 2026-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INR101 | Diagnostic / imaging agent | 7 unknown | Intravenous |